The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the importance of referral decisions in lymphoma management. While most patients are effectively treated in the community setting, Dr Shah emphasizes that those who experience early relapse or disease progression often have a poorer prognosis and may benefit from consultation with a lymphoma specialist. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
